Tumor cells often overexpress immune checkpoint proteins, including CD47, for immune evasion.[2] Activation of RTKs in GBM is a crucial driver event in GBM development.[8b] However, whether these oncogenic signalings regulate CD47 expression is not known. This evidence concerns the gene CD47 and glioblastoma.